Advisory & Consulting
The science is rarely the problem. Adoption is.
New biomarkers and genomic tests reach the evidence base years before they reach an ordinary consultation. I work on closing that gap: testing what actually changes clinical decisions, building the pathway around it, teaching it to other clinicians, and explaining it publicly.
I am now taking on a small number of paid advisory commitments alongside clinical practice, working with diagnostics, genomics and health technology companies. The perspective I bring is a practising GP, CQC registered manager and clinic founder, rather than an academic or a career consultant.
How I Work
I co-founded Coyne Medical in 2016 and am the CQC registered manager for its regulated activities. That means I carry real accountability for clinical governance, information governance and regulatory compliance, across a clinic seeing over 11,000 consultations a year.
It also means I have taken new diagnostics from literature to live service more than once, and know where that process breaks: pricing, consent, result communication, clinician confidence, and what happens when a patient asks a question the evidence cannot yet answer.
Most advisory input to healthcare companies comes from academics who do not run services, or consultants who do not see patients. I do both, which is usually most useful on the questions that decide whether a product is adopted or quietly abandoned.
The most dangerous risk factor is the one that's never been measured. The same is true of the assumption no one tested with a real clinician.
Lp(a) is a largely genetic risk factor present in roughly one in five people, and it is still absent from most routine lipid panels. I test for it, act on it, and teach other clinicians how to interpret and communicate the result.
The link between the oral microbiome and cardiovascular, metabolic and neurodegenerative risk is moving from literature into practice. Coyne Medical was among the first UK clinics to offer oral genome screening, and I built the clinical pathway around it.
I carry a PALB2 variant myself, which shaped how the clinic approaches genetic screening. I work on who should be tested, how results are communicated, and where current NHS thresholds leave people unscreened.
PGx is well evidenced and barely used in UK primary care. I am building the service model for how it fits an ordinary consultation, which is the gap between the science and adoption.
What I Take On
Each engagement is scoped separately rather than bundled, and I will say early if I do not think I can add real value.
Standing or project-based advisory roles for diagnostics, genomics and health technology companies, bringing a practising primary-care perspective rather than an academic one.
How a test, device or service actually lands in a consultation: who orders it, what the clinician says about the result, and what happens next. This is usually where adoption succeeds or fails.
Independent assessment of clinical claims, evidence base and regulatory position for investors and acquirers looking at healthcare and diagnostics assets.
CPD-accredited course development, clinical accuracy review of consumer-facing health claims, and education programmes for clinical or patient audiences.
Conferences, clinical education sessions, panels and podcasts on cardiovascular prevention, genomics and preventive medicine.
Open to non-executive and board appointments where the clinical, regulatory and founder perspective is genuinely useful to the board rather than decorative.
Get in Touch
A short note on the company, the stage you are at, and where you think a clinical perspective would help is enough to start.
I will come back to you within a few working days on whether it is a fit.
Direct to me, not through an agency.
Handled by my press office. See recent coverage.